[Inhibition of eIF families expression and angiogenesis for human laryngeal carcinoma by elemene administration].
OBJECTIVE
To investigate the inhibitory effect of elemene on laryngeal carcinoma (Hep-2 cells) xenograft growth in nude mice and its mechanisms, and to explore the relationship between the expression of eukaryotic initiation factor families (eIF4E & eIF4G) and angiogenesis factors (bFGF & VEGF) after the administration of elemene.


METHODS
Human laryngeal carcinoma cells from Hep-2 cell strain were transplanted subcutaneously to BALB/c-nu/nu nude mice to produce tumors (42 nude mice were separated into seven groups to be treated by intraperitoneal injection). The tumor volume, tumor weight and tumor inhibition rate were evaluated, the expression of eIF4E, eIF4G, bFGF, VEGF and microvessel density were estimated by paraffin-embedded sections of seven groups' tumor samples analyzed utilizing immunohistochemical streptavidin peroxidase technique.


RESULTS
Elemene could inhibit the tumor growth in vivo. A significant suppression of tumor growth was observed when the dosage was increased. The tumor inhibition rates (IR) of elemene 50 mg/kg, 100 mg/kg and 200 mg/kg treated group were 5.2% , 41.7% and 50. 5% respectively. The IR of 100 mg/kg elemene (41.7%) was not significantly different with that of 3 mg/kg cisplatin (44.6%), and the IR of the drug combination (100 mg/kg elemene + 3 mg/kg cisplatin) was 51.2%. Compared with control groups the protein expression of eIF4E, eIF4G, bFGF and VEGF were significantly inhibited by elemene (P < 0.05), and the microvessel density in elemene treated groups decreased (P < 0.05). The tumor inhibition rate of combined elemene 100 mg/kg and cisplatin 3 mg/kg was 51.2%.


CONCLUSIONS
Elemene could inhibit the subcutaneous plantation of human laryngeal carcinoma in nude mice and its mechanism may be associated with inhibited expression of eIF families and angiogenesis factors. The combination of elemene and cisplatin could promote the synergistic effect on chemotherapy in the target tumor cells.
Tao
Lei
L
Department of Otorhinolaryngology, Eye Ear Nose & Throat Hospital of Fudan University, Shanghai 200031, China.
Zhou
Liang
L
Zheng
Lu-ying
LY
Yao
Ming
M
D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000098:blood supply* / Q000473:pathology; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology; D039561:Eukaryotic Initiation Factor-4E / Q000378:metabolism; D039603:Eukaryotic Initiation Factor-4G / Q000378:metabolism; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D006801:Humans; D007822:Laryngeal Neoplasms / Q000098:blood supply* / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic; D012717:Sesquiterpenes / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
D039561:Eukaryotic Initiation Factor-4E; D039603:Eukaryotic Initiation Factor-4G; D012717:Sesquiterpenes; D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2; C038905:elemene; D002945:Cisplatin